Lonza launches extra pluripotent cell lines
Lonza has expended its stem cell portfolio to offer hMSCs for translational and cell therapy research.
Lonza has expended its stem cell portfolio to offer hMSCs for translational and cell therapy research.
KeyPlants has been selected for the design and engineering of a 600,000L plasma processing facility operated by Russia’s MasterPlasma.